Barclays
NRIX icon

Barclays’s Nurix Therapeutics NRIX Stock Holding History

Barclays’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$545K Sell
22,482
-1,698
-7% -$28.9K ﹤0.01% 3162
2026
Q1 		$375K Sell
24,180
-232,504
-91% -$3.86M ﹤0.01% 3348
2025
Q4 		$4.87M Buy
256,684
+11,589
+5% +$166K ﹤0.01% 2240
2025
Q3 		$2.26M Sell
245,095
-9,775
-4% -$102K ﹤0.01% 2803
2025
Q2 		$2.9M Buy
254,870
+110,095
+76% +$1.19M ﹤0.01% 2557
2025
Q1 		$1.72M Sell
144,775
-4,561
-3% -$76.3K ﹤0.01% 2734
2024
Q4 		$2.81M Buy
149,336
+20,992
+16% +$481K ﹤0.01% 2644
2024
Q3 		$2.88M Buy
128,344
+56,190
+78% +$1.27M ﹤0.01% 2547
2024
Q2 		$1.51M Buy
72,154
+24,639
+52% +$384K ﹤0.01% 2338
2024
Q1 		$698K Sell
47,515
-21,224
-31% -$228K ﹤0.01% 3374
2023
Q4 		$709K Buy
68,739
+1,272
+2% +$8.72K ﹤0.01% 3669
2023
Q3 		$530K Sell
67,467
-1,524
-2% -$13.9K ﹤0.01% 2770
2023
Q2 		$689K Sell
68,991
-3,156
-4% -$32.2K ﹤0.01% 2556
2023
Q1 		$641K Sell
72,147
-27,510
-28% -$287K ﹤0.01% 3085
2022
Q4 		$1.09M Buy
99,657
+15,166
+18% +$183K ﹤0.01% 2715
2022
Q3 		$1.1M Buy
84,491
+81,760
+2,994% +$1.29M ﹤0.01% 2163
2022
Q2 		$34K Sell
2,731
-2,448
-47% -$27.7K ﹤0.01% 4195
2022
Q1 		$72K Buy
+5,179
New +$91.9K ﹤0.01% 3940

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's NRIX Position: Q2 2026 in Review

Barclays reduced its Nurix Therapeutics (NRIX) stake by 7% in Q2 2026, selling an estimated $28.9K and leaving 22,482 shares worth $545K. The position accounts for ﹤0.01% of the portfolio, ranked #3162.

Barclays first reported a position in NRIX in Q1 2022 and has held it in 18 quarters since. The position peaked at $4.87M in Q4 2025. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Barclays held 22,482 shares of Nurix Therapeutics worth $545K as of Q2 2026.
  • Barclays sold 1,698 Nurix Therapeutics shares in Q2 2026, an estimated $28.9K.
  • Nurix Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3162 holding.
  • Barclays first reported a position in Nurix Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Nurix Therapeutics position peaked at $4.87M in Q4 2025.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.